Recently I wrote an article on Idenix Pharmaceuticals (NASDAQ:IDIX), and since then the company has issued its 2nd quarter earnings with updates on their pipeline and Seth Klarman's Baupost has reported their holdings in Idenix. I will review what was discussed on the call and give my thoughts.
As I discussed in my previous article, safety is a large concern with the development of HCV drugs and poses the largest risk in an investment in Idenix. During the call, the major focus was around the update on IDX719 and pre-clinically held IDX2963.
IDX719 is the drug furthest along Idenix's development pipeline that I believe to be under-appreciated by the market. The pan-genotypic nature of IDX719 is heads and...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|